Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Urinary Bladder Neoplasms 18Pancreatic Neoplasms 17Lung Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Biliary Tract Neoplasms 10Urethral Neoplasms 9Lymphoma 8Uterine Cervical Neoplasms 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Large-Cell, Anaplastic 4Hodgkin Disease 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Sarcoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Salivary Gland Neoplasms 2Recurrent Uterine Corpus Sarcoma 2Recurrence 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Immunoblastic Lymphadenopathy 2Fallopian Tube Neoplasms 2Adenocarcinoma of Lung 2

Interventions

venetoclax 1tafasitamab 1glofitamab 1Rituximab 1Interviews as Topic 1Gemcitabine 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, B-Cell × Gemcitabine × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡